Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.LGC has announced that it is applying its HyBeacons genotyping technology to Europe's first-ever large scale trial of pharmacogenetic-guided anticoagulation therapy.
Subscribe to our email newsletter
The company also reported that the first patient within the trial has been successfully genotyped and treatment has been initiated.
LGC is collaborating with researchers from six European countries in the two-year EU trial, which is intended to demonstrate that a patient’s genotype plays an important role in the effective prescribing of anticoagulation (anti-blood-clotting) drugs such as Warfarin.
The study, which will involve 3000 patients, will use LGC’s HyBeacons technology to determine a patient’s genotype directly from blood.
The HyBeacons assay will be performed using a new point-of-care-instrument developed and manufactured by OptiGene.
The methodology designed enables the clinical staff to work with tiny blood sample and the whole procedure of genotyping a patient to determine the appropriate dose of anticoagulant drug takes less than two hours.
This trial aims to improve significantly the time within target INR range by adjusting the initial dosage of the anticoagulant drug based on the patient’s genotype.
The European Pharmacogenetics of Anticoagulant Therapy (EU-PACT) trial is funded by the Seventh Framework Program of the EU.
The two-armed, single-blind randomised controlled trial will test the effectiveness of dosing regimens that include genetic factors compared with dosing regimens without these factors.